Molecular biologists are at the forefront of the genome editing technology, exploring its immense potential for diagnostics, therapeutics and other out-of-the-box applications. This puts them in a perfect position to share the current advancements in genetic engineering and discuss ongoing challenges and limitations of the technology. We thus approached various molecular biologists to debunk the misconceptions surfaced during our survey. This can be found in #CasAsks: Survey.
Our team therefore hopes to become a bridge between the scientists who have the in-depth knowledge on genome editing and the general public who will be the eventual consumer of this technology. In this post, we distilled the keynotes highlighted by the expert scientists during our interviews to provide the general public with a wider perspective on the issue of genome editing.
Difference between revisions of "Team:NUS Singapore-Sci/Cas Asks Interview"
| Line 4: | Line 4: | ||
<title> NUS Singapore Science: InterLab </title> | <title> NUS Singapore Science: InterLab </title> | ||
<meta charset="UTF-8"> | <meta charset="UTF-8"> | ||
| + | |||
| + | <style> | ||
| + | .centertext{ | ||
| + | text-align:center; | ||
| + | font-size:20px; | ||
| + | } | ||
| + | |||
| + | </style> | ||
| + | |||
</head> | </head> | ||
| Line 42: | Line 51: | ||
Dr. Ho’s research interest lies in global health law and ethics, research ethics and policy, as well as health policy and governance (more information can be found <a href="http://cbme.nus.edu.sg/people/all-staff/dr-calvin-ho" style="text-decoration:none;font-thickness:normal;">here</a>). | Dr. Ho’s research interest lies in global health law and ethics, research ethics and policy, as well as health policy and governance (more information can be found <a href="http://cbme.nus.edu.sg/people/all-staff/dr-calvin-ho" style="text-decoration:none;font-thickness:normal;">here</a>). | ||
| + | </div> | ||
| + | |||
| + | <div class="numberedsection"> | ||
| + | Keynotes from Interview | ||
| + | </div> | ||
| + | |||
| + | <div class="centertext"> | ||
| + | <strong>1) CRISPR technology has great potential in the near future, especially for therapeutics </strong> <br> | ||
| + | |||
| + | “There’s definitely potential there, there [are] thousands of people and companies working on these things and some of these ideas will be translated to the clinic eventually.” <br> - Dr. Matias Autio <br><br> | ||
| + | |||
| + | |||
| + | |||
</div> | </div> | ||
Revision as of 19:56, 17 October 2018
Bridging the Gap: Interview keynote with expert scientists and bioethicists
Profile of our interviewees
Dr. Kon Oi Lian
is currently a Division head of the National Cancer Centre Singapore and has a Honorary Joint Professor position at the Department of Biochemistry in Yong Loo Lin School of Medicine, National University of Singapore (NUS).
Dr. Kon’s research focuses on cell therapy research in metabolic diseases. Currently, she is working on introducing a therapeutic gene to primary mammalian cells using zinc finger nucleases that aims to treat Haemophilia B (more information can be found here).
Dr. Matias Autio Currently a Senior Research Fellow in Professor Roger Foo’s Lab at A*STAR, Singapore.
Dr. Autio is researching on genome editing in stem cell models using the CRISPR technology. Foo’s Lab works on various projects related to the cardiac epigenome and heart-related diseases. (more information can be found here).
Dr. Calvin Ho Currently an Assistant Professor at the Centre for Biomedical Ethics at the Yong Loo Lin School of Medicine, National University of Singapore (NUS) and the co-Head of the World Health Organization Collaborator Centre on Bioethics, Singapore.
Dr. Ho’s research interest lies in global health law and ethics, research ethics and policy, as well as health policy and governance (more information can be found here).
is currently a Division head of the National Cancer Centre Singapore and has a Honorary Joint Professor position at the Department of Biochemistry in Yong Loo Lin School of Medicine, National University of Singapore (NUS).
Dr. Kon’s research focuses on cell therapy research in metabolic diseases. Currently, she is working on introducing a therapeutic gene to primary mammalian cells using zinc finger nucleases that aims to treat Haemophilia B (more information can be found here).
Dr. Matias Autio Currently a Senior Research Fellow in Professor Roger Foo’s Lab at A*STAR, Singapore.
Dr. Autio is researching on genome editing in stem cell models using the CRISPR technology. Foo’s Lab works on various projects related to the cardiac epigenome and heart-related diseases. (more information can be found here).
Dr. Calvin Ho Currently an Assistant Professor at the Centre for Biomedical Ethics at the Yong Loo Lin School of Medicine, National University of Singapore (NUS) and the co-Head of the World Health Organization Collaborator Centre on Bioethics, Singapore.
Dr. Ho’s research interest lies in global health law and ethics, research ethics and policy, as well as health policy and governance (more information can be found here).
Keynotes from Interview
1) CRISPR technology has great potential in the near future, especially for therapeutics
“There’s definitely potential there, there [are] thousands of people and companies working on these things and some of these ideas will be translated to the clinic eventually.”
- Dr. Matias Autio
“There’s definitely potential there, there [are] thousands of people and companies working on these things and some of these ideas will be translated to the clinic eventually.”
- Dr. Matias Autio